U.S. Water Utilities Stock News

NYSE:MRSH
NYSE:MRSHInsurance

Formula 1 Partnership and AI Push Could Be A Game Changer For Marsh & McLennan Companies (MRSH)

In late April 2026, Marsh, a business of Marsh & McLennan Companies, announced a multi-year global partnership with Formula 1 as its first Official Risk Partner and Official Insurance Brokering Partner, alongside prominent trackside branding, curated race experiences, and a new content series on risk decision-making. Around the same time, Oliver Wyman, another Marsh & McLennan business, created senior AI-focused leadership roles to accelerate AI-enabled integration and transformation across...
NasdaqGS:QURE
NasdaqGS:QUREBiotechs

A Look At uniQure (QURE) Valuation After Q1 Results And AMT-130 Regulatory Progress

uniQure (QURE) is in focus after first quarter results showed revenue of US$3.56 million and a net loss of US$53.54 million, alongside fresh regulatory progress for its Huntington’s disease gene therapy, AMT-130. See our latest analysis for uniQure. The stock has reacted strongly to the recent earnings update and regulatory progress on AMT-130, with a 1-month share price return of 79.84% and a 1-year total shareholder return of 110.34%, which may indicate building momentum rather than a...
NYSE:COTY
NYSE:COTYPersonal Products

A Look At Coty (COTY) Valuation After Weak Earnings, Withdrawn Guidance And Lawsuit Uncertainty

Coty (COTY) is back in focus after recent earnings showed pressure on sales, wider losses, and withdrawn guidance, while a securities class action lawsuit adds a separate layer of uncertainty for shareholders. See our latest analysis for Coty. Recent selling pressure has been heavy, with the 1 year total shareholder return down 50.7% and the 3 year total shareholder return down 78.2%. At the same time, the 30 day share price return is up 13.82%, suggesting only a short term bounce after weak...
NYSE:AA
NYSE:AAMetals and Mining

Should Alcoa’s ESOP Shelf and Dividend Move Require Action From Alcoa (AA) Investors?

In early May 2026, Alcoa Corporation filed a US$506.08 million shelf registration for 8,000,000 common shares linked to its employee stock ownership plan and confirmed a quarterly dividend of US$0.10 per share payable on June 5, 2026. This combination of an employee-focused equity program and a maintained cash dividend underscores Alcoa’s parallel focus on workforce ownership and ongoing capital returns. With Wells Fargo’s upgrade reflecting increased confidence in Alcoa’s outlook, we’ll now...
NYSE:CTRI
NYSE:CTRIConstruction

Why Centuri Holdings (CTRI) Is Down 12.1% After Strong Q1 Revenue And Backlog Growth

In the first quarter of 2026, Centuri Holdings reported revenue of US$723.17 million, up from US$550.08 million a year earlier, while reducing its net loss to US$9.53 million from US$17.94 million. Alongside this improvement, the company grew gross profit sharply, expanded its backlog to about US$6.50 billion, and reaffirmed its 2026 guidance while outlining multi-year growth targets. With revenue rising strongly and the backlog reaching about US$6.50 billion, we’ll now examine how this...
NYSE:WAT
NYSE:WATLife Sciences

Waters (WAT) Valuation Check After Q1 Beat And Higher 2026 Guidance

Waters (WAT) is back in focus after first quarter 2026 results beat expectations, aided by strong organic growth and the BD Biosciences and Diagnostic Solutions acquisitions, alongside higher full year 2026 financial guidance. See our latest analysis for Waters. Investors have responded quickly to the upgraded 2026 guidance, with the stock delivering a 17.64% 7 day share price return and an 8.60% 90 day share price return. However, year to date the share price return is down 7.02%, while the...
NasdaqCM:KOPN
NasdaqCM:KOPNSemiconductor

Assessing Kopin (KOPN) Valuation After Major AI And Defense Contract Wins

Recent news around Kopin (KOPN) centers on its partnership with Fabric.AI, including a MicroLED Neural I/o chip program for AI data centers, new development funding, and fresh leadership for this joint effort. See our latest analysis for Kopin. The recent news flow appears to have coincided with sharp share price momentum, with a 30 day share price return of 103.38% and a 90 day share price return of 130.21%. This has contributed to a very strong 1 year total shareholder return of 249.03% and...
NasdaqGS:PTCT
NasdaqGS:PTCTBiotechs

Why PTC Therapeutics (PTCT) Is Up 12.5% After Beating Q1 Estimates And Lifting 2026 Guidance

In early May 2026, PTC Therapeutics reported first-quarter revenue of US$272.55 million versus US$1.18 billion a year earlier, swinging from net income of US$866.56 million to a net loss of US$2.81 million while still beating analyst expectations on both revenue and earnings per share. The company also released positive 24-month interim data for Huntington’s disease therapy votoplam and raised its 2026 product revenue guidance, underscoring how a strong Sephience launch and advancing...
NasdaqGS:NVAX
NasdaqGS:NVAXBiotechs

Novavax (NVAX) Valuation Check After Pfizer Licensing Deal And Partnership-Led Earnings Beat

Novavax (NVAX) recently reported first quarter 2026 results that beat revenue and loss expectations, helped by a US$30 million upfront payment from a new Pfizer licensing deal and fresh Matrix M partnership activity. See our latest analysis for Novavax. The stock has rallied strongly in recent months, with a 7 day share price return of 16.5% and a year to date share price return of 29.5%, although the 5 year total shareholder return remains down 92.4%. If you are looking beyond vaccines and...